Cellular and Molecular Immunology · 2022 · 59 citations · 46 references
Life SciencesImmunologyInfectious DiseasesImmunizationVaccinologyVirologyAdjuvant DevelopmentVaccinationVaccine DeliveryVaccine-preventable DiseasesViral VaccinesVirus-like Particle VaccinesCoronavirus VaccinesSars-cov-2 InfectionVaccine Adjuvant TherapyVaccine-induced Antiviral ImmunityViral-like Particle VaccinesVirus-like Particle AdjuvanticityVirus-like Particle ImmunogenicityVirus-like Particle Vaccine Platforms
Abstract Although antivirals are important tools to control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, effective vaccines are essential to control the current coronavirus disease 2019 (COVID-19) pandemic. Plant-derived virus-like particle (VLP) vaccine candidates have previously demonstrated immunogenicity and efficacy against influenza. Here, we report the immunogenicity and protection induced in rhesus macaques by intramuscular injections of a VLP bearing a SARS-CoV-2 spike protein (CoVLP) vaccine candidate formulated with or without Adjuvant System 03 (AS03) or cytidine-phospho-guanosine (CpG) 1018. Although a single dose of the unadjuvanted CoVLP vaccine candidate stimulated humoral and cell-mediated immune responses, booster immunization (at 28 days after priming) and adjuvant administration significantly improved both responses, with higher immunogenicity and protection provided by the AS03-adjuvanted CoVLP. Fifteen micrograms of CoVLP adjuvanted with AS03 induced a polyfunctional interleukin-2 (IL-2)-driven response and IL-4 expression in CD4 T cells. Animals were challenged by multiple routes (i.e., intratracheal, intranasal, and ocular) with a total viral dose of 10 6 plaque-forming units of SARS-CoV-2. Lower viral replication in nasal swabs and bronchoalveolar lavage fluid (BALF) as well as fewer SARS-CoV-2-infected cells and immune cell infiltrates in the lungs concomitant with reduced levels of proinflammatory cytokines and chemotactic factors in the BALF were observed in animals immunized with the CoVLP adjuvanted with AS03. No clinical, pathologic, or virologic evidence of vaccine-associated enhanced disease was observed in vaccinated animals. The CoVLP adjuvanted with AS03 was therefore selected for vaccine development and clinical trials.
46
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett et al. · Science · 2020 · 9.8K citations · Full text
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan, José Mateus, Yu Kato et al. · Science · 2021 · 3K citations · Full text
The Architecture of SARS-CoV-2 Transcriptome
Dong-Wan Kim, Joo-Yeon Lee, Jeong‐Sun Yang et al. · Cell · 2020 · 2.4K citations · Full text